Neuphoria Therapeutics (NEUP) Research & Development (2023 - 2025)
Neuphoria Therapeutics' Research & Development was $697,723 in fiscal Q2 2026 (quarter ended Dec 31, 2025), down 59.8% from $1.74 million a year earlier and down 81.6% from the prior quarter.
Neuphoria Therapeutics (NEUP) Research & Development (2023 - 2025) Analysis & Trends
On a trailing twelve-month basis, Neuphoria Therapeutics' Research & Development was $9.85 million through Dec 31, 2025, up 24.2% year-over-year; for FY2025 (ended Jun 30, 2025), it came in at $9.01 million, down 4.4% from FY2024.
- Research & Development shows a five-year compound annual growth rate of 18.1% (FY2020 to FY2025).
- In earlier fiscal years, Research & Development was $9.42 million in FY2024 (-28.0%), $13.07 million in FY2023 (+14.1%), $11.46 million in FY2022 (+158.3%) and $4.44 million in FY2021 (+13.4%).
- The fiscal Q2 2026 figure marks the lowest quarterly Research & Development in data going back to fiscal Q1 2024.
- Compared with a year earlier, Research & Development was higher in three of the last six quarters, with growth averaging 7.0%.
- Per Business Quant data, NEUP's Research & Development in the three fiscal quarters before Q2 2026 was $3.79 million (Q1 2026), $3.75 million (Q4 2025) and $1.62 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,170.23 Bn | 1,138.82 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 648.85 Bn | 568.71 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 504.91 Bn | 478.02 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 368.25 Bn | 322.63 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 303.41 Bn | 267.40 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 268.65 Bn | 242.33 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 242.96 Bn | 198.36 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 195.01 Bn | 169.21 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 173.22 Bn | 119.87 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Neuphoria Therapeutics | 437.56 Mn | 362.37 Mn | - | - |
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 697,723.00 |
| Sep 30, 2025 | 3.79 Mn |
| Jun 30, 2025 | 3.75 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 3.10 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Dec 31, 2023 | 2.03 Mn |
| Sep 30, 2023 | 3.09 Mn |
Neuphoria Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=NEUP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "NEUP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=NEUP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();